+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 4Years +
All Genders
ID06971731

Phase 3 Study Evaluating Safety and Efficacy of JNT-517 Compared to Placebo in Treating Phenylketonuria with Two Treatment Periods

Led by Otsuka Pharmaceutical Development & Commercialization, Inc. · Updated on 2026-10-21

120

Participants Needed

26

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, effectiveness, and how the body processes a drug called JNT-517 in children, adolescents, and adults who have phenylketonuria, a condition affecting phenylalanine levels in the body. This Phase 3 study aims to understand the impact of JNT-517 on managing phenylalanine levels and related symptoms in people with this condition. Participants will be randomly assigned to receive either JNT-517 or a matching placebo orally twice daily for an initial 6-week period. After this, eligible participants will continue with JNT-517 treatment for an additional 46 weeks, with dosing based on age. This study includes two treatment periods a blinded 6-week phase followed by an open-label 46-week phase where all participants receive JNT-517. During the study, participants will undergo regular assessments including measurement of plasma phenylalanine levels at various timepoints, evaluations of attention-related symptoms, dietary intake monitoring, and safety evaluations. Researchers will track changes in phenylalanine from baseline through week 6 and week 52, as well as treatment-emergent adverse events. The total participation duration includes 6 weeks of blinded treatment plus 46 weeks of open-label treatment, with ongoing monitoring throughout.

CONDITIONS

Brief Title

A Study of JNT-517 in Participants With Phenylketonuria (PKU)

Research Team

O

Otsuka Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here